This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Christian Klein, PhD
Head Oncology Programs at Roche Innovation Center Zurich


Christian Klein, Distinguished Scientist, is Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery 3 at the Roche Innovation Center Zurich (Roche Pharma Research & Early Development, pRED). Since 06/2019 he also acts as Site Head of RICZ. He specialized in the discovery, engineering, validation and preclinical development of therapeutic (bispecific) antibodies for cancer immunotherapy. During his 18 year tenure at Roche he has made major contributions to the preclinical development and approvals of GAZYVA(RO) (obinutuzumab, GA101), and to the preclinical development of 15 bispecific antibodies, immunocytokines and antibody fusion proteins entering clinical trials. He lead(s) research teams developping Roche’s bispecific antibody technologies e.g. the CrossMab, immunocytokine and T-cell bispecific antibody platforms, and contributed to preclinical research on the IGF-1R mAb teprotumumab (R1507, TEPEZZA), and the MDM2 inhibitor idasanutlin (RG7388). He co-authored >130 publications, contributed to >150 patent applications on cancer therapy, therapeutic/bispecific antibodies and antibody engineering, and is an external lecturer (PD) in biochemistry at the Ludwig-Maximilians University (LMU) in Munich since 2017.

Agenda Sessions

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #7: CELL ENGAGERS FOR THE INNATE IMMUNE SYSTEM - To prepare for this discussion/Q&A, attendees should view the presentations from Session #7 in the Watch On-Demand Sessions Tab prior to this session

  • PD1-IL2v, A Novel PD-1 Targeted Immunocytokine for Cancer Immunotherapy

    On Demand